Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Lee, Seung-Pyo | - |
dc.contributor.author | Park, Kyung-Woo | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Cho, Young-Seok | - |
dc.contributor.author | Youn, Tae-Jin | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Bae, Jang-Ho | - |
dc.contributor.author | Kwon, Taek-Geun | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Cho, Myeong-Chan | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-07T16:01:26Z | - |
dc.date.available | 2021-09-07T16:01:26Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-01-18 | - |
dc.identifier.issn | 0735-1097 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/113260 | - |
dc.description.abstract | Objectives We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES). Background The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention in previous studies. Methods In a randomized multicenter trial, we enrolled 960 patients who received DES. They were randomized to receive either dual antiplatelet therapy (DAT) (aspirin and clopidogrel) or triple antiplatelet therapy (TAT) (aspirin, clopidogrel, and cilostazol) for 6 months. Primary end point was the composite of cardiac death, nonfatal myocardial infarction, ischemic stroke, or target lesion revascularization (TLR). Secondary end points were P2Y(12) reaction unit (PRU) measured with the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) at discharge and at 6 months after the index procedure. All-cause death, stent thrombosis, and each component of the primary end point at 6 months were other secondary end points. Analysis was done on an intention-to-treat basis. Results At 6 months' follow-up, there was no difference in the primary end point between the 2 groups (8.5% in TAT vs. 9.2% in DAT, p = 0.74). In secondary end point analysis, the TAT group achieved lower PRU levels than the DAT group both at discharge (206.6 +/- 90.3 PRU vs. 232.2 +/- 80.3 PRU, p < 0.001) and at 6 months (210.7 +/- 87.9 PRU vs. 255.7 +/- 73.7 PRU, p < 0.001). In the Cox proportional hazards analysis, lesion length (>= 28 mm, hazard ratio [HR]: 2.10, 95% confidence interval [CI]: 1.25 to 3.52), and PRU level at discharge (every increase in tertile, HR: 1.61, 95% CI: 1.16 to 2.25) were predictors of the primary end point, but not the use of cilostazol (HR: 0.90, 95% CI: 0.54 to 1.52). Conclusions Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828) (J Am Coll Cardiol 2011;57:280-9) (C) 2011 by the American College of Cardiology Foundation | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | RESIDUAL PLATELET REACTIVITY | - |
dc.subject | LONG-TERM OUTCOMES | - |
dc.subject | OF-CARE ASSAY | - |
dc.subject | MYOCARDIAL-INFARCTION | - |
dc.subject | CLOPIDOGREL RESISTANCE | - |
dc.subject | DIABETES-MELLITUS | - |
dc.subject | ARTERY-DISEASE | - |
dc.subject | RESTENOSIS | - |
dc.subject | INTERVENTION | - |
dc.subject | ASPIRIN | - |
dc.title | Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1016/j.jacc.2010.08.631 | - |
dc.identifier.scopusid | 2-s2.0-78651287537 | - |
dc.identifier.wosid | 000286133900006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.57, no.3, pp.280 - 289 | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | - |
dc.citation.title | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | - |
dc.citation.volume | 57 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 280 | - |
dc.citation.endPage | 289 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | RESIDUAL PLATELET REACTIVITY | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | OF-CARE ASSAY | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | CLOPIDOGREL RESISTANCE | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | ARTERY-DISEASE | - |
dc.subject.keywordPlus | RESTENOSIS | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordAuthor | cilostazol | - |
dc.subject.keywordAuthor | DES | - |
dc.subject.keywordAuthor | platelet reactivity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.